[ Price : $8.95]
An investigation by the journal Science questions the data behind a Parkinsons drug under development by Prothena and based on fal...[ Price : $8.95]
FDA grants Eli Lilly full approval for Retevmo (selpercatinib) for certain adult and pediatric patients two years of age and older...[ Price : $8.95]
AbbVie files a BLA seeking accelerated approval for Teliso-V (telisotuzumab vedotin) and its use in certain adult patients with pr...[ Price : $8.95]
AbbVie says a pivotal Phase 3 (TEMPO-1) trial for tavapadon in early Parkinsons disease met its primary and secondary endpoints.[ Price : $8.95]
Federal Register notice: FDA proposes to reclassify qualitative hepatitis B virus (HBV) antigen assays, qualitative and quantitati...[ Price : $8.95]
Four Ropes & Gray attorneys identify the key provisions in three new FDA clinical trial modernization guidances.[ Price : $8.95]
Federal Register notice: FDA determines for patent extension purposes the regulatory review period for SpringWorks Therapeutics Og...[ Price : $8.95]
Pfizer withdraws its sickle cell disease drug Oxbryta from all approved markets after data show the overall benefit does not outwe...